Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) Fair Value & Analysis
Healthcare · CN · Market cap 6.3B CNY (≈ $933M) · ISIN CNE100005YT4
What is Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A really worth?
A solid business, but trading 43% above our fair value of ¥10.05.
Strengths
Risks
For context
Fair value as of: Aug 21, 2026
From 24 valuation models · updated 15 days ago
Share price −2.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥12.56). The favourable scenario is already priced in.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
42‑month range ¥9.26 – ¥29.58 · fair‑value band ¥7.53 – ¥12.56 · the ¥14.40 price screens above the ¥10.05 fair value. Dashed = 300-day average. As of Aug 21, 2026.
Analysis
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) currently trades at ¥14.40, while our model-based Fair Value estimate is ¥10.05, implying the stock looks roughly 43.3% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥32.22 per share, and 15 of the 24 models we run sit above the ¥14.40 price. Bear case: the Asset-Based group reads lowest at ¥3.51, and 9 of the 24 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A generated revenue of 5.6B CNY at a net margin of 3.7%. Revenue grew 12.2% year over year. It earns a return on equity of 10.8%. The stock trades on a trailing P/E of 27.2. Fundamentals as of Aug 21, 2026
Our scenario range runs from ¥7.53 (bear case) to ¥12.56 (bull case); at ¥14.40, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 51% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −30%, 301408 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.2910 per share, which is 2.9 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models (¥32.22) versus Asset-Based (¥3.51). Highest evidence: FCF DCF (73).
Notify me when 301408 reaches fair value
Put 301408 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Anhui Huaren Health Pharmaceutical Co., Ltd. operates in the medical and healthcare industry. It offers products for oral and throat, nourishing, heat-clearing, respiratory system, and gynecology, as well as provides vitamins and minerals, and detoxifying products. In addition, it provides supplements, and nutrition and health products.
Full company description
Anhui Huaren Health Pharmaceutical Co., Ltd. operates in the medical and healthcare industry. It offers products for oral and throat, nourishing, heat-clearing, respiratory system, and gynecology, as well as provides vitamins and minerals, and detoxifying products. In addition, it provides supplements, and nutrition and health products. Anhui Huaren Health Pharmaceutical Co., Ltd. was founded in 2001 and is based in Hefei, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A reported revenue of 5.5B CNY in FY2025 versus 2.3B CNY in FY2021, a compound +23.8%/yr. Reported net income was 191M CNY in FY2025, compounding +28.7%/yr from FY2021.
301408 screens 43% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 57 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$38.86 | HK$33.31 | −14% |
| Alibaba Health Information Technology Limited 0241 | HK$3.26 | HK$2.04 | −37% |
| Yifeng Pharmacy Chain Co 603939 | ¥22.90 | ¥29.07 | +27% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.79 | ¥23.86 | +27% |
| MedPlus Health Services Limited MEDPLUS | ₹656.80 | ₹191.97 | −71% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥13.44 | ¥10.57 | −21% |
| Yixintang Pharmaceutical Group 002727 | ¥11.61 | ¥9.45 | −19% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.30 | ¥5.91 | −56% |
| Apotea AB APOTEA | kr 74.15 | kr 46.46 | −37% |
| Luyan Pharma Co 002788 | ¥10.96 | ¥15.91 | +45% |
Compare Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) overvalued or undervalued?
What is the fair value of 301408?
What is the quality score of 301408?
What is the revenue of Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408)?
What is the net profit margin of 301408?
Does Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A pay a dividend?
Watch Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A in the live analysis
One click puts Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.